'To identify tumor-intrinsic drivers of resistance, we quantified in-vitro response to CD19-directed chimeric antigen receptor T-cells (CD19-CAR) and bispecific antibodies (BsAb) across 46 B-NHL cell lines and measured their proteomic profiles at baseline. Among the proteins associated with poor in-vitro response was Serpin B9, an endogenous granzyme B inhibitor.'

#CART #immunotherapy #Immunology #immunooncology #Preprint

https://www.biorxiv.org/content/10.1101/2023.06.26.546507v1?med=mas